Exicure Shares Outstanding 2017-2021 | XCUR

Exicure shares outstanding from 2017 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Exicure Annual Shares Outstanding
(Millions of Shares)
2020 87
2019 58
2018 41
2017 10
2016 0
Exicure Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 88
2021-03-31 88
2020-12-31 87
2020-09-30 87
2020-06-30 87
2020-03-31 88
2019-12-31 58
2019-09-30 65
2019-06-30 44
2019-03-31 44
2018-12-31 41
2018-09-30 42
2018-06-30 39
2018-03-31 39
2017-12-31 10
2017-09-30 2
2017-06-30 0
2017-03-31 0
2016-12-31
2016-09-30 0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.103B $0.017B
Exicure Inc. is a clinical-stage biotechnology company. It is engaged in developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid technology. Exicure Inc. is based in IL, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57